PE Firm Sycamore Partners Acquires Walgreens in $23.7B Deal

What You Should Know: 

– Walgreens Boots Alliance (WBA) has announced a definitive agreement to be acquired by an entity affiliated with Sycamore Partners, a private equity firm specializing in retail, consumer, and distribution-related investments. 

– The total value of the transaction is estimated to be up to $23.7B.

Deal Structure and Shareholder Value

WBA shareholders will receive $11.45 per share in cash at closing, along with a non-transferable right (DAP Right) to receive up to $3.00 per share from the future monetization of WBA’s debt and equity interests in VillageMD, which includes Village Medical, Summit Health, and CityMD businesses. This brings the total potential consideration to $14.45 per share.

The deal represents a 29% premium over WBA’s closing share price on December 9, 2024, the day before initial media reports of a potential transaction, and a potential 63% premium if the DAP Rights reach their maximum value.

Strategic Rationale and Future Direction

Sycamore Partners’ acquisition aims to leverage WBA’s healthcare expertise and Sycamore’s retail and consumer services leadership. The company will continue to operate under the Walgreens and Boots brands, maintaining its headquarters in the Chicago area. The goal is to position WBA as the first choice for pharmacy, retail, and health services.

Transaction Details and Approvals

The WBA Board of Directors has unanimously approved the transaction, with Stefano Pessina and John Lederer recused. The deal is expected to close in the fourth quarter of calendar year 2025, subject to customary closing conditions, including shareholder and regulatory approvals. The transaction is not subject to a financing condition, as Sycamore has secured fully committed financing.

Upon completion, WBA’s common stock will be delisted from the Nasdaq Stock Market, and the company will become private.

“Go-Shop” Period and Shareholder Agreements

The agreement includes a 35-day “go-shop” period, allowing WBA to solicit alternative proposals. However, there is no guarantee of a superior offer.

WBA’s Executive Chairman, Stefano Pessina, and his holding company, owning approximately 17% of WBA’s shares, have entered into voting and reinvestment agreements. They will vote in favor of the transaction and reinvest their cash consideration, along with an additional investment, into the acquiring company, maintaining a significant equity stake.

VillageMD Value Maximization

A committee will be formed to maximize the value of WBA’s interests in VillageMD, considering various options, including operational enhancements and balance sheet strengthening. WBA shareholders will receive DAP Rights, with 70% of net proceeds from any VillageMD sale payable to DAP Right holders, up to $3.00 per share.